Major depressive disorder (MDD) is severely prevalent, and conventional monoaminergic
antidepressants gradually exhibit low therapeutic efficiency, especially for patients with …

Background: A growing body of evidence suggests that glutamatergic system, especially the
abnormalities of glutamate and N-methyl-D-aspartate (NMDA) receptors contribute to the …

There have been no recent advances in drug development for mood disorders in terms of
identifying drug targets that are mechanistically distinct from existing ones. As a result …

Accumulating evidence suggests that the glutamatergic system plays important roles in the
pathophysiology and treatment of major depressive disorder (MDD). Abnormalities in the …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …

Major depressive disorder (MDD) is a severe, debilitating medical illness that affects millions
of individuals worldwide. The young age of onset and chronicity of the disorder has a …

Depression is a common psychiatric condition characterized by affective, cognitive,
psychomotor, and neurovegetative symptoms that interfere with a person's ability to work …

Over the past 20 years, converging lines of evidence have both linked glutamatergic
dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic …

Current treatments for depression are less than optimal in terms of onset of action, response
and remission rates, and side-effect profiles. Glutamate is the major excitatory …